216060-23-0

Basic information

• Product Name: 4-(PYRAZIN-2-YL)BENZOIC ACID
• Synonyms: 4-(PYRAZIN-2-YL)BENZOIC ACID;4-(3,6-Dimethylpyrazin-2-yl)benzoic acid;4-(3-Chloropyrazin-2-yl)benzoic acid;4-(5-Methylthiophen-2-yl)benzoic acid;4-(6-Aminopyrazin-2-yl)benzoic acid;4-(6-Chloropyrazin-2-yl)benzoic acid
• CAS NO: 216060-23-0
• Molecular Formula: C₁₁H₈N₂O₂
• Molecular Weight: 200.19342
• Product Categories: Carboxylic Acids;Phenyls & Phenyl-Het;Carboxylic Acids;Phenyls & Phenyl-Het
• Mol File: 216060-23-0.mol

Chemical Properties

• Boiling Point: 396.413 °C at 760 mmHg
• Flash Point: 193.544 °C
• Appearance: /
• Density: 1.303 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C
• PKA: 3.62±0.10(Predicted)
• CAS DataBase Reference: 4-(PYRAZIN-2-YL)BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PYRAZIN-2-YL)BENZOIC ACID(216060-23-0)
• EPA Substance Registry System: 4-(PYRAZIN-2-YL)BENZOIC ACID(216060-23-0)

Safety Data

• Hazardous Substances Data: 216060-23-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(PYRAZIN-2-YL)BENZOIC ACID is used as a building block in organic synthesis for the development of new drugs, leveraging its structural properties to create compounds with potential therapeutic applications.
Used in Medicinal Chemistry:
4-(PYRAZIN-2-YL)BENZOIC ACID is used as a key component in drug discovery, where its derivatives are known to possess anti-inflammatory and anticancer properties, making it valuable for the creation of treatments targeting inflammation and cancer.
Used in Chemical Reactions:
4-(PYRAZIN-2-YL)BENZOIC ACID is used as a reagent, contributing to various chemical processes that require its specific chemical properties to achieve desired outcomes in synthesis.
Used in Molecular Biology:
4-(PYRAZIN-2-YL)BENZOIC ACID is used as a research tool in molecular biology, aiding in the study of biological processes and the development of new biological assays and techniques.

InChI:InChI=1/C11H8N2O2/c14-11(15)9-3-1-8(2-4-9)10-7-12-5-6-13-10/h1-7H,(H,14,15)

Upstream product

• 466634-84-4 4-pyrazin-2-yl benzoic acid methyl ester 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 
• 127406-08-0 4-pyrazin-2-yl-benzaldehyde 
• 14508-49-7 2-chloropyrazin 
• 14047-29-1 4-carboxyphenylboronic acid 
• 87199-17-5 4-formylphenylboronic acid, 

Downstream Products

• 1354353-58-4 N-(4-(2-methylpyridin-4-yl)benzyl)-4-(pyrazin-2-yl)benzamide 
• 1441810-67-8 C₄₁H₄₀N₄O₅ 
• 1354353-79-9 4-(pyrazin-2-yl)-N-(4-(2-(trifluoromethyl)pyridin-4-yl)benzyl)benzamide 
• 1354353-71-1 N-(2'-fluoro-(2,4'-bipyridinl-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-66-4 N-(3-fluoro-4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)benzyl)-4-(pyrazin-2-yl)benzamide 
• 1354353-59-5 N-((2'-methyl-[2,4'-bipyridin]-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 
• 1354354-39-4 N-((3-methyl-2'-(trifluoromethyl)-2,4'-bipyridin-5-yl)methyl)-4-(pyrazin-2-yl)benzamide 

Relevant articles and documents

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Design, synthesis, and evaluation of novel porcupine inhibitors featuring a fused 3-ring system based on the ‘reversed’ amide scaffold

The Wnt signaling pathway is an essential signal transduction pathway which leads to the regulation of cellular processes such as proliferation, differentiation and migration. Aberrant Wnt signaling is known to have an association with multiple cancers. Porcupine is an enzyme that catalyses the addition of palmitoleate to a serine residue in Wnt proteins, a process which is required for the secretion of Wnt proteins. Here we report the synthesis and structure–activity-relationship of the novel porcupine inhibitors based on a ‘reversed’ amide scaffold. The leading compound 53 was as potent as the clinical compound LGK974 in a cell based STF reporter gene assay. Compound 53 potently inhibited the secretion of Wnt3A, therefore was confirmed to be a porcupine inhibitor. Furthermore, compound 53 showed excellent chemical and plasma stabilities. However, the clearance of compound 53 in liver microsomal tests was moderate to high, and the solubility of compound 53 was suboptimal. Collective efforts toward further optimization of this novel tricyclic template to develop better porcupine inhibitors will be subsequently undertaken and reported in due course.

Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands

Seventeen biarylcarboxybenzamide derivatives were prepared for the study of their agonistic/antagonistic activities to the vanilloid receptor (VR1) in rat DRG neurons. The replacement of the piperazine moiety of the lead compound 1 with phenyl ring showed quite enhanced antagonistic activity. Among the prepared derivatives, N-(4-tert-butylphenyl)-4-pyridine-2-yl-benzamide (2, IC 50 = 31 nM) and N-(4-tert-butylphenyl)-4-(3-methylpyridine-2-yl) benzamide (3g, IC50 = 31 nM), showed 5-fold higher antagonistic activity than 1 in 45Ca2+-influx assay.

A convenient synthesis of heteroaryl benzoic acids via Suzuki reaction

An one step approach to heteroaryl benzoic acids from readily accessible heteroaryl halides and carboxybenzene boronic acids is described. The Suzuki coupling is carried out in the presence of Pd(PPh3)4 and sodium carbonate in aqueous acetonitrile. The scope and limitations of the reaction are discussed.